The FDA, JAMA, and others think blood from those who recovered from COVID-19 could benefit those with the illness.

Anjeso and a new Advil formulation target pain, while Nurtec™ and Vyepti™ target migraines.

A new seizure drug has been approved, and a nerve growth drug advances in clinical trials.

Does the active ingredient in magic mushrooms have a future in mental health?

With CBD products widely available and advertised for so many ailments, claimants could be using CBD without insurers knowing.

A biosimilar to Humira is approved, the FDA Fast Tracks a PTSD drug, and more.

Indicated for various gastrointestinal concerns, these recalls could impact certain workers’ comp patients.

Nine generic versions of Lyrica (pregabalin) have been approved for the treatment of five different medical conditions.

Generic versions of Ultram (tramadol hydrochloride) tablets and Dyloject (diclofenac sodium) injections have been approved by the FDA.

Orphengesic Forte has received a decision date of August 14, 2019.